相关实验视频
Updated: Jun 29, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.2K
梅波利祖马布在过敏和非过敏喘患者中的实际有效性
Jared Silver1, Andrea Steffens2, Benjamin Chastek2
1Medical Affairs, GSK, Durham, NC, USA.
Journal of asthma and allergy
|March 28, 2024
概括
梅波利祖马布在过敏和非过敏的严重喘患者中有效降低了喘恶化和口服皮质类固醇的使用. 这表明,无论喘表型如何,梅波利祖马布的实际效益都是如此.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的喘影响全球数以百万计的人,过敏和非过敏的表型带来了不同的临床挑战.
- 在各种严重喘群体中,对像梅波利祖马布这样的向治疗的现实数据仍然有限.
- 了解不同表型的治疗疗效对于优化患者护理至关重要.
研究的目的:
- 为了评估mepolizumab在患有严重喘的患者中的实际有效性.
- 为了比较mepolizumab对恶化的影响和口服皮质类固醇 (OCS) 在过敏与非过敏喘表型中的使用.
- 为了评估mepolizumab在严重喘中的效用,无论过敏状态如何.
主要方法:
- 使用行政索赔数据 (Optum研究数据库) 的回顾性队列研究.
- 纳入标准:年龄≥6岁的患有喘的患者和≥2个mepolizumab索赔.
- 通过诊断代码,药物和实验室数据确定的表型 (过敏/非过敏);在开始使用梅波利祖马布12个月前和后评估结果.
主要成果:
- 在过敏 (3.2至2.1) 和非过敏 (2.5至1.7) 队列中观察到与喘相关的恶化显著减少 (p < 0.001).
- 梅波利祖马布的使用导致了OCS使用的显著减少:平均索赔减少了33.3% (过敏) 和41.4% (非过敏);平均每日剂量分别减少了30.6%和45.4% (p < 0.001).
- 过敏和非过敏群体之间减少恶化或OCS使用的幅度没有显著差异.
结论:
- 梅波利祖马布显著降低了严重喘患者的喘恶化和OCS需求.
- 这项研究证明了梅波利祖马布在过敏和非过敏喘表型中的实际有效性.
- 这些发现支持mepolizumab作为一种有价值的治疗选择,用于严重的喘,独立于过敏状态.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
288
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
288
01:24Antiasthma Drugs: Methylxanthines
226
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
226
01:19Antiasthma Drugs: Leukotriene Modifiers
291
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
291
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
261
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
261
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
297
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
297
01:20Asthma: Pathogenesis and Management
394
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
394